All In Biotech

Drug Trial Radar · NCT06525220

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 699 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

699

Actual

Start

Sep 25, 2024

Primary completion

Jan 2028

Study completion Jul 2030

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • PetosemtamabDrug

    MCLA-158

  • PembrolizumabDrug

    Humanized Antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 3 years
  2. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)Time frame: Up to approximately 2 years

Locations

202 sites in 28 countries. Site status is shown where the registry gives one.

  • Site 164

    Mobile, Alabama

  • Site 36

    La Jolla, California

  • Site 27

    Los Angeles, California

  • Site 16

    Palo Alto, California

  • Site 19

    Newark, Delaware

  • Site 108

    Washington D.C., District of Columbia

  • Site 14

    Fort Myers, Florida

  • Site 8

    Orlando, Florida

  • Site 21

    St. Petersburg, Florida

  • Site 20

    West Palm Beach, Florida

  • Site 171

    Atlanta, Georgia

  • Site 197

    Chicago, Illinois

  • Site 50

    Chicago, Illinois

  • Site 2

    Louisville, Kentucky

  • Site 162

    Baton Rouge, Louisiana

  • Site 155

    Minneapolis, Minnesota

  • Site 168

    St Louis, Missouri

  • Site 94

    Hackensack, New Jersey

  • Site 6

    Albuquerque, New Mexico

  • Site 113

    Durham, North Carolina

  • Site 118

    Winston-Salem, North Carolina

  • Site 191

    Cleveland, Ohio

  • Site 43

    Philadelphia, Pennsylvania

  • Site 153

    Philadelphia, Pennsylvania

  • Site 154

    Philadelphia, Pennsylvania

  • Site 89

    Chattanooga, Tennessee

  • Site 115

    Memphis, Tennessee

  • Site 88

    Nashville, Tennessee

  • Site 22

    Austin, Texas

  • Site 1

    Houston, Texas

  • Site 18

    Plano, Texas

  • Site 17

    Sugar Land, Texas

  • Site 15

    Tyler, Texas

  • Site 10

    Salt Lake City, Utah

  • Site 12

    Blacksburg, Virginia

  • Site 23

    Norfolk, Virginia

  • Site 170

    CABA, Argentina

  • Site 96

    CABA, Argentina

  • Site 31

    Córdoba, Argentina

  • Site 30

    La Rioja, Argentina

Showing 40 of 202 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.